In a subgroup analysis of the IMpower150 trial, it was observed that combining atezolizumab with bevacizumab, carboplatin, and paclitaxel (BCP) yielded superior outcomes in terms of progression-free survival (PFS) and objective response rate (ORR) compared to BCP alone in non-squamous NSCLC patients with EGFR mutations or ALK rearrangements resistant to TKIs [7,8]. Here, ALK is linked to non-small cell lung carcinoma.